High Tide (HITI) Q1 2026

Q2 2026 Q1 2026 Q4 2025 Q3 2025

Earnings

High Tide Inc. Delivered a mixed but broadly encouraging fiscal first quarter, posting earnings per share of $0.01 against a consensus estimate of $0.00, a beat of 265%, even as revenue of $130.43 million came in below the $173.80 million analysts ha… Read more High Tide Inc. Delivered a mixed but broadly encouraging fiscal first quarter, posting earnings per share of $0.01 against a consensus estimate of $0.00, a beat of 265%, even as revenue of $130.43 million came in below the $173.80 million analysts had expected. The top line still grew 25.2% year-over-year, propelled by the first full quarter of contribution from Remexian Pharma GmbH, the German medical cannabis distribution subsidiary acquired in September 2025, which added $18.27 million to consolidated revenue while the core Canadian bricks-and-mortar network contributed $109.48 million. Adjusted EBITDA climbed 62% to $8.38 million, free cash flow swung to positive $2.15 million from negative $1.39 million a year ago, and the net loss narrowed sharply to $257,453 from $1.97 million. Looking ahead, management is targeting 20 to 30 new Canna Cabana openings in calendar 2026, expects margin improvement in the medical cannabis distribution segment beginning in Q2 as better-priced Canadian biomass enters the supply chain, and anticipates entering the UK medical cannabis market within 12 months.